Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Aug 17;11(1):31.
doi: 10.1186/s13561-021-00329-9.

Cost analysis of chronic obstructive pulmonary disease (COPD): a systematic review

Celia Gutiérrez Villegas  1 , María Paz-Zulueta  2   3 , Manuel Herrero-Montes  4   5 , Paula Parás-Bravo  4   5 , María Madrazo Pérez  4
Affiliations
Review

Cost analysis of chronic obstructive pulmonary disease (COPD): a systematic review

Celia Gutiérrez Villegas et al. Health Econ Rev. .

Abstract

Background: Chronic Obstructive Pulmonary Disease (COPD) is a treatable disease with a high prevalence, and high morbidity associated with significant socioeconomic costs.

Objective: To carry out a systematic review of the literature to analyze the main cost studies associated with COPD, in order to determine the main factors that influence the costs of the disease.

Methods: Searches were conducted in PubMed, SCOPUS and Web of Science databases for cost studies on COPD published in English, between the years 2015 and 2020. The search terms were "COPD" OR "pulmonary disease, chronic obstructive", "cost*" OR "cost of illness", "economic impact" AND "burden of disease". The inclusion criteria included the identification of reported cost of the disease, economic burden, medical care expenses or use resources for COPD, the methodology used, data sources, and variables studied.

Results: 18 publications were analyzed: 17 included direct health costs, 6 included direct non-medical costs, 12 analyzed indirect costs and two reported intangible costs. Most of the studies reported data for developed and European countries, with direct costs being the most studied. Trends were observed in multiple studies of direct and healthcare costs for European countries measured by patient and year, where the higher costs were associated with more severe COPD and a frequent history of exacerbations. The highest costs reported corresponded to hospitalizations and the associated pharmacological treatment. The importance of the loss of productivity and premature retirement within the profile of the COPD patient was also highlighted as the main generator of indirect costs of the disease.

Conclusion: COPD generates substantial costs for the health system, mainly related to moderate to severe stages and the exacerbations and complications entailed. It is important to strengthen health systems with monitoring, evaluation and health education models that allow these patients to remain stable to avoid decompensation and subsequent hospitalizations.

Keywords: Chronic obstructive; Cost of illness; Health care costs; Investments; Pulmonary disease; Systematic review.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Fig. 1
Fig. 1
Flow diagram of literature search
See this image and copyright information in PMC

References

    1. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary Disease [Monograph on the Internet]. USA: Global Initiative for Chronic Obstructive Lung Disease; 2020 [Accessed Dec 15, 2020]. Available at : https://goldcopd.org/wpcontent/uploads/2019/12/GOLD-2020-FINAL-ver1.2-03...
    1. Grupo de trabajo de GesEPOC. Guía de Práctica Clínica para el Diagnóstico y Tratamiento de Pacientes con Enfermedad Pulmonar Obstructiva Crónica (EPOC) – Guía española de la EPOC (GesEPOC). Versión 2017. Arch Bronconeumol [Internet] 2017 junio [citado 20 diciembre 2020]; 53(1): 2–64. 10.1016/S0300-2896(12)70035-2.
    1. González Del Castillo J, Candel FJ, de la Fuente Federico Gordo J et al. Manejo integral del paciente con exacerbación aguda de la enfermedad pulmonar. Rev Esq Quimioter [Internet] 2018 October [Accessed 20 Dec 2020]; 31(5):461–84. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6194861/ - PMC - PubMed
    1. Cerezo-Lajas A, Rodríguez-Jimeno E, Gallo-González V et al. Mortalidad y factores asociados al reingreso en pacientes dados de alta tras una exacerbación aguda de EPOC. Rev Patol Respit [Internet] 2018 September [Accessed 22 Dec 2020]; 21(3):78–85. Available at: https://www.revistadepatologiarespiratoria.org/descargas/PR_21-3_79-85.pdf
    1. Urrútia G, Bonfill X. Declaración PRISMA: una propuesta para mejorar la publicación de revisiones sistemáticas y metaanálisis. Med Clin (Barc) [Internet] 2010;135(11):507–511. doi: 10.1016/j.medcli.2010.01.015. - DOI - PubMed

LinkOut - more resources